Medicine and Dentistry
Non Small Cell Lung Cancer
100%
Overall Survival
86%
Lung Cancer
74%
Systematic Review
74%
Small Cell Lung Cancer
54%
Meta-Analysis
45%
Cohort Analysis
39%
Erlotinib
37%
Hyponatremia
37%
Progression Free Survival
35%
Biological Marker
33%
Lymphocyte
29%
Neutrophil
27%
Platelet
25%
Fibrinolysis
24%
Bleeding
24%
Prognostic Factor
24%
Hazard Ratio
22%
Splenectomy
21%
Positron Emission Tomography
18%
Positron Emission Tomography
18%
Epidermal Growth Factor Receptor
18%
Neoplasm
18%
Cancer Incidence
18%
Hyperfibrinolysis
18%
Anaplastic Lymphoma Kinase
18%
Solid Malignant Neoplasm
18%
Circulating Tumor DNA
18%
Brain Cancer
18%
Reticulocytosis
18%
Cell-Free DNA
18%
Direct Oral Anticoagulant
18%
Blood Stasis
18%
Alkaline Phosphatase
18%
Reticulocyte
18%
Anemia
18%
Prognostication
16%
Positron Emission Tomography-Computed Tomography
13%
Fluorine-18
10%
Malignant Neoplasm
9%
Brain Tumor
9%
Ganglioglioma
9%
Hemoglobins
9%
Targeted Therapy
9%
Proportional Hazards Model
8%
Laboratory Information System
8%
Cancer Registry
8%
D-Dimer
7%
Diagnosis
7%
Glucose Uptake
7%
Biochemistry, Genetics and Molecular Biology
Erlotinib
56%
Epidermal Growth Factor Receptor
56%
Biological Variation
56%
Overall Survival
48%
Receptor Gene
43%
Reference Value
42%
Circulating Tumor DNA
37%
Light Chain
37%
Neurofilament
37%
Allele
25%
Progression Free Survival
24%
Cohort Study
21%
X-Ray Computed Tomography
21%
Genetic Polymorphism
18%
Gene Polymorphism
18%
Neutrophil-To-Lymphocyte Ratio
18%
Anaplastic Lymphoma Kinase
18%
Immunoassay
18%
Hyponatremia
18%
Medical Record
18%
Protein C Deficiency
18%
Chemoluminescence
18%
Tumor Volume
18%
Fibrin Clot
18%
Autoantibodies
18%
Alkaline Phosphatase
18%
Platelet Count
18%
Hemoglobin A2
18%
Glial Fibrillary Acidic Protein
18%
Normal Human
15%
Genotyping
14%
Next Generation Sequencing
13%
Droplet Digital Polymerase Chain Reaction
12%
Blood Clot Lysis
11%
Tyrosine Kinase Inhibitor
9%
Monospecific Antibody
9%
Positron Emission Tomography-Computed Tomography
8%
Genetic Risk
7%
Laboratory Information System
5%
Cell Mutant
5%
Leukocyte Count
5%
Colon
5%
Multivariate Analysis
5%
Medline
5%
Web of Science
5%
Embase
5%
Scopus
5%
Immunology and Microbiology
Overall Survival
60%
Reference Value
57%
Biological Variation
56%
Blood Plasma
33%
Positron Emission Tomography
26%
Next Generation Sequencing
24%
Immunoassay
23%
Progression Free Survival
21%
Fibrinolysis
20%
Reticulocyte Count
18%
Reticulocyte
18%
Lymphocyte
18%
Autoantibodies
18%
Hemostasis
18%
Monospecific Antibody
18%
Coronary Artery
18%
DNA Polymorphism
18%
Light Chain
18%
Neurofilament
18%
Chemoluminescence
18%
Tumor Volume
18%
Prognostic Biomarker
18%
Droplet Digital Polymerase Chain Reaction
18%
Epidermal Growth Factor
18%
Receptor Gene
18%
Turnaround Time
18%
Electronic Health Record
18%
Neutrophil
16%
Colon
12%
Allele
11%
Blood Clot Lysis
10%
Fibrin Clot
10%
Diabetes Mellitus Type 1
9%
Erythrocyte
9%
Blood Transfusion
9%
Positron Emission Tomography-Computed Tomography
8%
Glucose Transport
7%
Web of Science
7%
Embase
7%
Medline
7%
X-Ray Computed Tomography
6%
Cell Mutant
5%